Placeholder Banner

BIO Welcomes Support of Vice President Biden in Fight to Cure Cancer

January 12, 2016

Washington, D.C. (January 12, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding Vice President Joe Biden’s “moon shot” initiative to find a cure for cancer.

“We applaud Vice President Biden for his leadership in advancing the fight to cure cancer. The process of discovering new cures and treatments for patients in need relies upon an ecosystem of innovation in which all stakeholders, including government agencies and regulators, academic research institutions, private industry, and patient groups, play a critical role.

“America’s innovative biopharmaceutical companies stand ready to work with the Vice President to bring about the day when no cancer patient is faced with a virtual death sentence. Our industry has a long track record of finding breakthrough treatments to once-deadly diseases, including HIV/AIDS, Hepatitis C and an ever-increasing list of cancers. Scientific advancements in the field of medicine have never been as promising as they are today, and we look forward to playing our part in bringing them to patients in need.”

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

BIO CEO & Investor Conference
February 8-9, 2016
New York, New York

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden


###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…